Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP9GFZ)

• Drug Name: DAU-6285 Drug Info
• Synonyms: Dau 6285; CHEMBL552854; (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 6-methoxy-2-oxo-3H-benzimidazole-1-carboxylate; AC1L2WHB; GTPL246; SCHEMBL2945410; CHEMBL1194556; PDSP1_000035; BDBM50007863; PDSP2_000035; PDSP1_001680; PDSP2_001663; L000897; 6-Methoxy-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester

Indication

Disease Entry	ICD 11	Status	REF
Vomiting	MD90	Terminated	[1] , [2]

• Cross-matching ID:
  PubChem CID: 129927
  CAS Number: CAS 123258-98-0
  TTD Drug ID: DMP9GFZ

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 4 receptor (HTR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisapride	DMY7PED	Gastroesophageal reflux disease	DA22.Z	Approved	[4]
Tegaserod	DM3XYD1	Irritable bowel syndrome	DD91.0	Approved	[5]
R0-93877	DMM4U9G	Constipation	DD91.1	Approved	[6]
HTF 919	DM78G6F	Constipation	DD91.1	Approved	[7]
Mosapride	DM2VOQ3	N. A.	N. A.	Phase 4	[8]
Renzapride	DM7HQNX	Irritable bowel syndrome	DD91.0	Phase 3	[9]
Lintopride	DMSHGWN	Nausea	MD90	Phase 2	[10]
TD-8954	DM3C9NV	Gastrointestinal disease	DE2Z	Phase 2	[11]
SB-207266A	DM27KFY	Irritable bowel syndrome	DD91.0	Phase 2	[6]
YKP-GI	DM740LV	Constipation	DD91.1	Phase 2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 4 receptor (HTR4)	TT07C3Y	5HT4R_HUMAN	Modulator	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 246).
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002002)
• [3] The novel 5-HT4 receptor antagonist DAU 6285 antagonizes 5-hydroxytryptamine-induced tachycardia in pigs. Eur J Pharmacol. 1993 Mar 23;233(2-3):295-7.
• [4] Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90.
• [5] Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
• [6] Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
• [7] 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58.
• [8] The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37.
• [9] Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
• [10] The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
• [11] The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011 May 30;2:25.
• [12] A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015 Apr;13(4):701-8.e1.